Physician
Oncology
Dr. Ralph G. Zinner, MD
|
|
Give Review
Ralph Zinner practices Oncology. He researched medicine at Georgetown University School of Medicine. Georgetown University School of Medicine is ranked 49 in research and 84 in primary care medicine Dr. Ralph G. Zinner is a published doctor and has 63 publications published. The lastest was: 'Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review).' Doctor Ralph G. Zinner, MD is registered with Medicare.
Publications
- Pemetrexed clinical studies in performance status 2 patients with non-small cell lung Cancer (Review).
- P1.09Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced Cancer.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizu...
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid Tumors.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- Targeted PI3K/AKT/mTOR therapy for metastatic Carcinomas of the cervix: A phase I clinical experience.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Outcomes of patients with advanced Cancer and KRAS mutations in phase I clinical trials.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- Outcomes of patients with metastatic cervical Cancer in a phase I clinical trials program.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Re...
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced Cancer.
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid Tumors.
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung Cancer.
- Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patie...
- Outcomes of patients with advanced non-small cell lung Cancer treated in a phase I clinic.
- Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab foll...
- Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung Cancer as frontline and second-line therapy.
- Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung Cancer in two phase II trials.
- Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung Cancer: NCCTG and SWOG study N0426.
- Algorithmic guided screening of drug combinations of arbitrary size for activity against Cancer cells.
- Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III...
- Images in clinical medicine. Reversal of Laryngeal paresis.
- Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung Cancer.
- Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory Cancer.
- Many patients 80 years and older with advanced non-small cell lung Cancer (NSCLC) can tolerate chemotherapy.
- A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung Cancer.
- Asian ethnicity as a predictor of response in patients with non-small-cell lung Cancer treated with gefitinib on an expanded access program.
- Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung Cancer.
- Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory Cancer.
- Pemetrexed in advanced NSCLC: a review of the clinical data.
- Effects of amifostine on Acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
- Pemetrexed in the treatment of advanced non-small-cell lung Cancer: a review of the clinical data.
- Prostate-specific antitumor activity by probasin promoter-directed p202 expression.
- Fingerprinting the circulating repertoire of antibodies from Cancer patients.
- Phase I study of azacitidine and oxaliplatin in patients with advanced Cancers that have relapsed or are refractory to any platinum therapy.
- FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors.
- Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung Cancer: report of a phase II tr...
- Non-small cell lung Cancer clinical trials with trastuzumab: their foundation and preliminary results.
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell Lung carcinoma: potential for decreased toxicity an...
- New targets for the treatment of advanced non-small cell lung Cancer.
- Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell Cancer of the head and neck.
- Short-term restaging of patients with non-small cell lung Cancer receiving chemotherapy.
- Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid Tumors.
- Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid Tumors.
- Gene-based therapy: novel approaches.
- Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell Lung canc...
- The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast Cancer cells.
- Three dimensional Analysis of histone methylation patterns in normal and tumor cell nuclei.
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal Cancer.
- MET nucleotide variations and amplification in advanced ovarian Cancer: characteristics and outcomes with c-Met inhibitors.
- Mutation profiling in cholangioCarcinoma: prognostic and therapeutic implications.
Schools
Georgetown Univ Sch Of Med
Thos Jefferson University Hospital
University Tx Med School At Houston
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Thomas Jefferson University -
Georgetown University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1326132457 | |
| NPPES Provider LastName | ZINNER | |
| NPPES Provider FirstName | RALPH | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 303.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 4.29 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326132457 |
| Last Name Of The Provider | ZINNER |
| First Name Of The Provider | RALPH |
| View All |
Similar Doctors
|
|
Dr. Frank V. Fossella, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Frankie A. Holmes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yvonne H. Sada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent Valero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonard A. Zwelling, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paulo M. Hoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheridan M. Diaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George R. Blumenschein Jr., MD |